Given that both ROS1+ NSCLC tumor specimens and ROS1+ patient-derived cell lines were used in this study, evaluating the key transcriptomic differences between tumor and cell line samples is particularly important. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.